Management of hepatitis B reactivation in patients receiving cancer chemotherapy

被引：26
作者：
Huang, Yi-Wen [2 ,3 ,4 ,5 ]
Chung, Raymond T. [1 ]
机构：
[1] Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Boston, MA 02114 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA USA
[3] Cathay Gen Hosp, Med Ctr, Ctr Liver, Taipei, Taiwan
[4] Taipei Med Univ, Sch Med, Taipei, Taiwan
[5] Natl Taiwan Univ Coll Med & Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2012年 / 5卷 / 05期
关键词：
cancer; chemotherapy; HBV reactivation; hepatitis B virus; lamivudine; prophylaxis; VIRUS HBV REACTIVATION; NON-HODGKINS-LYMPHOMA; CYTOTOXIC CHEMOTHERAPY; BREAST-CANCER; PROPHYLACTIC LAMIVUDINE; PREEMPTIVE LAMIVUDINE; HEPATOCELLULAR-CARCINOMA; HEMATOLOGIC MALIGNANCIES; LIVER-TRANSPLANTATION; POSITIVE PATIENTS;
D O I：
10.1177/1756283X12450245
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.
引用
收藏
页码：359 / 370
页数：12
相关论文
共 84 条
[1]   Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours [J].
Alexopoulos, CG ;
Vaslamatzis, W ;
Hatzidimitriou, G .
BRITISH JOURNAL OF CANCER, 1999, 81 (01) :69-74
[2]   American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases [J].
Artz, Andrew S. ;
Somerfield, Mark R. ;
Feld, Jordan J. ;
Giusti, Andrew F. ;
Kramer, Barnett S. ;
Sabichi, Anita L. ;
Zon, Robin T. ;
Wong, Sandra L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3199-3202
[3]   A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].
Chang, TT ;
Gish, RG ;
de Man, R ;
Gadano, A ;
Sollano, J ;
Chao, YC ;
Lok, AS ;
Han, KH ;
Goodman, Z ;
Zhu, J ;
Cross, A ;
DeHertogh, D ;
Wilber, R ;
Colonno, R ;
Apelian, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010
[4]   Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma [J].
Cheng, AL ;
Hsiung, CA ;
Su, IJ ;
Chen, PJ ;
Chang, MC ;
Tsao, CJ ;
Kao, WY ;
Uen, WC ;
Hsu, CH ;
Tien, HF ;
Chao, TY ;
Chen, LT ;
Whang-Peng, J .
HEPATOLOGY, 2003, 37 (06) :1320-1328
[5]   Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients [J].
Cheng, JCH ;
Liu, MC ;
Tsai, SY ;
Fang, WT ;
Jian, JJM ;
Sung, JL .
CANCER, 2004, 101 (09) :2126-2133
[6]   Promyelocytic Leukemia Nuclear Bodies Link the DNA Damage Repair Pathway with Hepatitis B Virus Replication: Implications for Hepatitis B Virus Exacerbation during Chemotherapy and Radiotherapy [J].
Chung, Yih-Lin ;
Tsai, Tzung-Yuan .
MOLECULAR CANCER RESEARCH, 2009, 7 (10) :1672-1685
[7]   Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H [J].
Cortelezzi, Agostino ;
Vigano, Mauro ;
Zilioli, Vittorio R. ;
Fantini, Norma N. ;
Pasquini, Maria C. ;
Deliliers, Giorgio Lambertenghi ;
Colombo, Massimo ;
Lampertico, Pietro .
JOURNAL OF CLINICAL VIROLOGY, 2006, 35 (04) :467-469
[8]   Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP [J].
Dai, MS ;
Chao, TY ;
Kao, WY ;
Shyu, RY ;
Liu, TM .
ANNALS OF HEMATOLOGY, 2004, 83 (12) :769-774
[9]   Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration [J].
Dai, MS ;
Wu, PF ;
Shyu, RY ;
Lu, JJ ;
Chao, TY .
LIVER INTERNATIONAL, 2004, 24 (06) :540-546
[10]   Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal follow-up [J].
Dai, MS ;
Wu, PF ;
Lu, JJ ;
Shyu, RY ;
Chao, TY .
SUPPORTIVE CARE IN CANCER, 2004, 12 (03) :191-196
123456789